CervoMed (NASDAQ:CRVO – Get Free Report) and BeOne Medicines (NASDAQ:ONC – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, profitability, valuation and dividends.
Profitability
This table compares CervoMed and BeOne Medicines’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| CervoMed | N/A | -156.02% | -128.34% |
| BeOne Medicines | 10.70% | 14.23% | 7.82% |
Institutional & Insider Ownership
25.2% of CervoMed shares are held by institutional investors. Comparatively, 48.5% of BeOne Medicines shares are held by institutional investors. 35.8% of CervoMed shares are held by insiders. Comparatively, 6.2% of BeOne Medicines shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares CervoMed and BeOne Medicines”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| CervoMed | $4.01 million | 8.68 | -$26.97 million | ($3.22) | -0.71 |
| BeOne Medicines | $5.34 billion | 7.61 | $286.93 million | $5.68 | 65.16 |
BeOne Medicines has higher revenue and earnings than CervoMed. CervoMed is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for CervoMed and BeOne Medicines, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| CervoMed | 1 | 1 | 4 | 1 | 2.71 |
| BeOne Medicines | 0 | 2 | 13 | 2 | 3.00 |
CervoMed presently has a consensus price target of $21.00, suggesting a potential upside of 812.65%. BeOne Medicines has a consensus price target of $407.07, suggesting a potential upside of 9.99%. Given CervoMed’s higher probable upside, equities analysts clearly believe CervoMed is more favorable than BeOne Medicines.
Risk and Volatility
CervoMed has a beta of -0.75, meaning that its share price is 175% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Summary
BeOne Medicines beats CervoMed on 12 of the 15 factors compared between the two stocks.
About CervoMed
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
About BeOne Medicines
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Receive News & Ratings for CervoMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CervoMed and related companies with MarketBeat.com's FREE daily email newsletter.
